"Designing Growth Strategies is in our DNA"
Region : | Published Date: Upcoming | Report ID: FBI100980| Status : Pipeline
Bacterial Meningitis, a type of meningitis, an infection caused in the membranes surrounding the brain and spinal cord of the body. Meningitis can be caused by bacteria, fungi, or a virus. Bacterial meningitis is the most serious type of meningitis. It can lead to death or permanent disability as the bacterial infection causes the brain tissue to swell, which then interferes with the blood flow resulting in paralysis or even stroke. Bacteria responsible for the meningeal cause are Streptococcus Pneumoniae, Group B Streptococcus, Hemophilus influenza, Listeria monocytogenes, and others. Symptoms of bacterial meningitis include high fever, headaches, and stiff neck. Other symptoms include nausea, vomiting, photophobia, and altered mental status.
Current treatment of bacterial meningitis includes the administration of antibiotics, corticosteroids, paracetamol, and others. Antibiotics such as asenicillin and cefotaxime are commonly used to treat bacterial meningitis as they kill bacteria and prevents the spread of infection in and around the brain tissues.
Pharmaceutical companies, along with various research institutes, have been focusing on studying and developing new treatment options for bacterial meningitis. For instance; DPT-IPV-Hib, which is being studied by Mitsubishi Tanabe Pharma Corporation is currently in phase-3 clinical trials for the study of safety, immunogenicity, and efficacy of DPT-IPV-Hib for protection against disease caused by meningococcal bacteria in infants.
To get details on market share, speak to our analyst
At present, around 40% of the pipeline candidates for Bacterial Meningitis are in the phase-3 clinical study. Majority of studies for the treatment of bacterial meningitis are carried by research institutes.
The report on ‘Bacterial Meningitis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bacterial Meningitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bacterial Meningitis.
The report on ‘Bacterial Meningitis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.